These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20520293)

  • 41. Ziprasidone augmentation for anxious depression.
    Ionescu DF; Shelton RC; Baer L; Meade KH; Swee MB; Fava M; Papakostas GI
    Int Clin Psychopharmacol; 2016 Nov; 31(6):341-6. PubMed ID: 27306192
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder.
    Patkar AA; Pae CU; Vöhringer PA; Mauer S; Narasimhan M; Dalley S; Loebel A; Masand PS; Ghaemi SN
    J Clin Psychopharmacol; 2015 Jun; 35(3):319-23. PubMed ID: 25882763
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Trial.
    Durgam S; Gommoll C; Forero G; Nunez R; Tang X; Mathews M; Sheehan DV
    J Clin Psychiatry; 2016 Dec; 77(12):1687-1694. PubMed ID: 27232052
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ziprasidone Augmentation of SSRI Antidepressants in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Pilot Study of Augmentation Therapy.
    Hamner MB; Hernandez-Tejada MA; Zuschlag ZD; Agbor-Tabi D; Huber M; Wang Z
    J Clin Psychopharmacol; 2019; 39(2):153-157. PubMed ID: 30640209
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictors of relapse in a study of duloxetine treatment for patients with generalized anxiety disorder.
    Bodkin JA; Allgulander C; Llorca PM; Spann ME; Walker DJ; Russell JM; Ball SG
    Hum Psychopharmacol; 2011 Apr; 26(3):258-66. PubMed ID: 21678494
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of Ziprasidone Augmentation of Escitalopram for Cognitive Symptoms of Major Depressive Disorder.
    Iovieno N; Shelton RC; Petrie SR; Cusin C; Fava M; Papakostas GI
    J Clin Psychiatry; 2018; 79(1):. PubMed ID: 28749091
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder.
    Rynn MA; Siqueland L; Rickels K
    Am J Psychiatry; 2001 Dec; 158(12):2008-14. PubMed ID: 11729017
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder.
    Fresquet A; Sust M; Lloret A; Murphy MF; Carter FJ; Campbell GM; Marion-Landais G
    Ann Pharmacother; 2000 Feb; 34(2):147-53. PubMed ID: 10676820
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder.
    Adams JB; Pyke RE; Costa J; Cutler NR; Schweizer E; Wilcox CS; Wisselink PG; Greiner M; Pierce MW; Pande AC
    J Clin Psychopharmacol; 1995 Dec; 15(6):428-34. PubMed ID: 8748432
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder.
    Baldwin DS; Loft H; Florea I
    Int Clin Psychopharmacol; 2012 Jul; 27(4):197-207. PubMed ID: 22475889
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The comparative clinical study of efficacy of Gamisoyo-San (Jiaweixiaoyaosan) on generalized anxiety disorder according to differently manufactured preparations: multicenter, randomized, double blind, placebo controlled trial.
    Park DM; Kim SH; Park YC; Kang WC; Lee SR; Jung IC
    J Ethnopharmacol; 2014 Dec; 158 Pt A():11-7. PubMed ID: 25456420
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder.
    Papakostas GI; Vitolo OV; Ishak WW; Rapaport MH; Zajecka JM; Kinrys G; Mischoulon D; Lipkin SH; Hails KA; Abrams J; Ward SG; Meisner A; Schoenfeld DA; Shelton RC; Winokur A; Okasha MS; Bari MA; Fava M
    J Clin Psychiatry; 2012 Dec; 73(12):1541-7. PubMed ID: 23290327
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study.
    Gommoll C; Forero G; Mathews M; Nunez R; Tang X; Durgam S; Sambunaris A
    Int Clin Psychopharmacol; 2015 Nov; 30(6):297-306. PubMed ID: 26291335
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacantha and Eschscholtzia californica) and magnesium in mild-to-moderate anxiety disorders.
    Hanus M; Lafon J; Mathieu M
    Curr Med Res Opin; 2004 Jan; 20(1):63-71. PubMed ID: 14741074
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder.
    Amsterdam JD; Li Y; Soeller I; Rockwell K; Mao JJ; Shults J
    J Clin Psychopharmacol; 2009 Aug; 29(4):378-82. PubMed ID: 19593179
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and efficacy of aviandr in patients with generalized anxiety disorder: A multicenter, randomized, double-blind, placebo-controlled, dose-finding, pilot study.
    Ivashchenko AA; Morozova MA; Vostokova NV; Beniashvily AG; Bukhanovskaya OA; Burminskiy DS; Egorova AN; Gluskina LY; Gorchakov DS; Karapetian RN; Kasimova LN; Kravchenko DV; Lepilkina TA; Merkulova EA; Mitkin OD; Penchul NA; Potanin SS; Rupchev GE; Ivachtchenko AV
    J Psychiatr Res; 2021 Nov; 143():436-444. PubMed ID: 34656876
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Open-label pilot study of ziprasidone for refractory generalized anxiety disorder.
    Snyderman SH; Rynn MA; Rickels K
    J Clin Psychopharmacol; 2005 Oct; 25(5):497-9. PubMed ID: 16160630
    [No Abstract]   [Full Text] [Related]  

  • 58. Efficacy of a special Kava extract (Piper methysticum) in patients with states of anxiety, tension and excitedness of non-mental origin - A double-blind placebo-controlled study of four weeks treatment.
    Lehmann E; Kinzler E; Friedemann J
    Phytomedicine; 1996 Sep; 3(2):113-9. PubMed ID: 23194958
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder.
    Dunayevich E; Erickson J; Levine L; Landbloom R; Schoepp DD; Tollefson GD
    Neuropsychopharmacology; 2008 Jun; 33(7):1603-10. PubMed ID: 17712352
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study.
    Aliyev NA; Aliyev ZN
    Eur Psychiatry; 2008 Mar; 23(2):109-14. PubMed ID: 17945470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.